SEC Tracker
Get the app
CYRX · XBRL financial data

Cryoport financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (CYRX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue5657*55585760*41454445*4849
Revenue from contracts with customers—year only374038year only41454445*4849
Cost of revenue3234*33323132*22242324*2626
Gross profit2423*22252527*19212122*2223
Research and development55*5544*4454*45
Selling, general and administrative3639*38363837*24272727*2828
Total operating expenses4193*431044241*28313132*3233
Operating income (loss)(17)(70)*(21)(79)(16)(14)*(9)(10)(10)(10)*(10)(10)
Interest expense11*1111*1111*01
Other income (expense)(3)5*1(1)(2)(6)*(0)(3)1(0)*(2)(0)
Income tax expense (benefit)0(1)*0010*0001*01
Net income (loss)(13)(62)*(19)(78)1(19)*(12)105(7)(12)*(11)(8)
Earnings per share, basic USD per share(0.31)(1.27)*(0.43)(1.62)(0.02)(0.38)*(0.28)2.05(0.18)(0.23)*(0.25)(0.20)
Earnings per share, diluted USD per share(0.31)(1.27)*(0.43)(1.62)(0.02)(0.38)*(0.28)2.05(0.18)(0.23)*(0.25)(0.20)
Weighted average shares, basic millions of shares4949*49494950*50505050*5050
Weighted average shares, diluted millions of shares4949*49494950*50505050*5050

Balance sheet

CSV

Fiscal quarters (CYRX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents59465046454536243256250273269
Short-term investments406410399381228216208183166161131127
Accounts receivable434241404346283335333936
Inventory292625242422232323232222
Prepaid and other current assets121011111112775866
Total current assets549535526502350342411489485476471460
Property and equipment, net758586878889808283859095
Right-of-use asset333331303047393840403940
Goodwill149108108525452211922222222
Total assets1,001958943852702703700774774765764756
Total current liabilities454649606165743031219225221
Lease liability, non-current302928272644383739393940
Total liabilities463469471452283302301259261262269266
Accumulated deficit(580)(642)(661)(739)(738)(757)(769)(668)(675)(689)(699)(708)
Total stockholders' equity538489472400419402399515513503495491
Total liabilities and equity1,001958943852702703700774774765764756
Common shares outstanding (cover page) millions of shares494949494950505050505051

Cash flows

CSV

Fiscal quarters (CYRX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(13)(62)*(19)(78)1(19)*(12)105(7)(12)*(11)(8)
Stock-based compensation66*5554*3232*22
Depreciation and amortization7*7*78*8*8*87*6*6*67*
Net cash from operating activities(2)*2*(3)(8)*0*(5)*(4)(7)*2*1*41*
Purchases of property and equipment9*12*44*4*5*34*3*5*109*
Net cash from investing activities19*(15)*613*154*3*6230*14*0*19(6)*
Share repurchases————————4*2*——
Net cash from financing activities(25)*(0)*1(9)*(155)*2*(0)(16)*(3)*(2)*01*
Net change in cash(8)*(13)*3(3)*(2)*1*2196*12*(5)*22(4)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Cryoport269491.1*50.6M— 10-QJun 30, 2026
Capricor Therapeutics21not reported(31)*58.1M7.6 quarters 10-QJun 30, 2026
REGENXBIO36108(62)*66.0M1.7 quarters 10-QJun 30, 2026
CytoDyn16not reported(7.7)1.5B2.1 quarters 10-QAug 31, 2026
Cronos Group4675324*368.4M— 10-QJun 30, 2026
CytomX Therapeutics171.4(18)*217.9M18.3 quarters 10-QJun 30, 2026
Oruka Therapeutics268not reported(33)*66.2M26.4 quarters 10-QJun 30, 2026
Carisma Therapeutics2.8451.9*41.8M— 10-QSep 30, 2025
Theravance Biopharma22021(7)*51.9M55.7 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.